Callan Capital’s Neurocrine Biosciences NBIX Stock Holding History

Callan Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-15,000	Closed	-$682K	–	55
2016 Q2	$682K	Sell	15,000 -7,000	-32%	-$322K	0.28%	33
2016 Q1	$870K	Buy	22,000 +7,000	+47%	+$278K	0.36%	30
2015 Q4	$849K	Hold	15,000	–	–	0.34%	33
2015 Q3	$597K	Hold	15,000	–	–	0.32%	32
2015 Q2	$716K	Sell	15,000 -5,000	-25%	-$212K	0.15%	49
2015 Q1	$794K	Sell	20,000 -7,365	-27%	-$263K	0.17%	47
2014 Q4	$611K	Hold	27,365	–	–	0.14%	51
2014 Q3	$429K	Hold	27,365	–	–	0.12%	51
2014 Q2	$406K	Hold	27,365	–	–	0.11%	52
2014 Q1	$441K	Buy	27,365 +5,500	+25%	+$94.1K	0.15%	41
2013 Q4	$204K	Buy	+21,865	New	+$213K	0.08%	44

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Callan Capital's NBIX Position: Q3 2016 in Review

Callan Capital sold out of Neurocrine Biosciences (NBIX) in Q3 2016, closing a stake of 15,000 shares — an estimated $682K sold.

Callan Capital first reported a position in NBIX in Q4 2013 and held it in 11 quarters. The position peaked at $870K in Q1 2016. 244 funds tracked by Wall St. Rank hold NBIX as of Q3 2016.

Callan Capital reported no remaining Neurocrine Biosciences position as of Q3 2016 after selling out during the quarter.
Callan Capital sold 15,000 Neurocrine Biosciences shares in Q3 2016, an estimated $682K.
Callan Capital first reported a position in Neurocrine Biosciences in Q4 2013 and held it in 11 quarters.
Callan Capital's Neurocrine Biosciences position peaked at $870K in Q1 2016.
244 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2016.

Based on Callan Capital's 13F filing for Q3 2016, filed 15 Nov 2016.